指南与共识肝病炎症性肠病胰腺与胆道疾病

AGA临床实践更新:妊娠相关胃肠道与肝病专家综述

AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.
指南 / 共识 · Gastroenterology · 2024-08-12

美国胃肠病协会(AGA)研究所临床实践更新基于已发表证据和专家意见,提出13条关于妊娠相关胃肠道与肝病管理的最佳实践建议,涵盖孕前咨询、恶心呕吐、便秘、内镜操作、炎症性肠病、胆汁淤积、肝病及乙肝等,未进行正式系统评价,故建议未附证据质量或推荐强度分级。

要点

  • 不应仅因妊娠而暂缓优化母体健康所需的操作、药物或干预,应个体化评估风险获益。
  • 妊娠期恶心呕吐应早期阶梯治疗:维生素B6联合多西拉敏、补液和营养,中重度可加用昂丹司琼等。
  • 炎症性肠病患者孕前、孕期及产后维持临床缓解至关重要,生物制剂应全程继续使用。

核心结论

  • 本专家综述基于已发表文献和专家意见提出13条最佳实践建议,用于妊娠相关胃肠道与肝病的临床管理,因未进行正式系统评价,建议未附正式的证据质量或推荐强度分级。

研究设计与样本

  • 美国胃肠病协会(AGA)研究所临床实践更新委员会和AGA理事会委托并批准,经内部同行评议和《Gastroenterology》标准外部同行评议,基于文献回顾和专家意见制定。

主要发现

  • 建议1:应鼓励有生育意愿的育龄人群接受多学科团队提供的孕前和避孕咨询以优化胃肠道和肝病。
  • 建议2:不应仅因患者妊娠而暂缓优化母体健康的操作、药物和其他干预,应在评估风险获益后个体化。
  • 建议3:复杂炎症性肠病、晚期肝硬化或肝移植妊娠患者的分娩协调应由多学科团队管理,最好在三级医疗中心进行。
  • 建议4:妊娠期恶心呕吐早期治疗可能减少进展为妊娠剧吐,阶梯治疗包括维生素B6和多西拉敏、补液和充足营养,中重度可需昂丹司琼、甲氧氯普胺、异丙嗪和静脉糖皮质激素。
  • 建议5:妊娠期便秘可能由激素、药物相关和生理变化引起,治疗选择包括膳食纤维、乳果糖和聚乙二醇类泻药。

关键数值与推荐

  • 建议6:择期内镜操作应推迟至产后,非紧急但必要的操作最好在妊娠中期进行;肝硬化孕妇应评估和治疗食管静脉曲张,建议妊娠中期(若孕前1年内未做)行上消化道内镜以指导非选择性β受体阻滞剂或内镜下静脉曲张套扎术。
  • 建议7:炎症性肠病患者孕前、孕期和产后临床缓解对改善妊娠结局至关重要;生物制剂应全程继续使用;甲氨蝶呤、沙利度胺和奥扎尼莫德必须在孕前至少6个月停用。
  • 建议8:妊娠期内镜逆行胰胆管造影术可用于胆总管结石、胆管炎和部分胆石性胰腺炎等紧急指征,最好在妊娠中期进行,若推迟可能对患者和胎儿健康不利应召集多学科团队决定其可行性。
  • 建议9:妊娠期胆囊切除术安全,无论妊娠期别腹腔镜为首选标准治疗,但最好在妊娠中期进行。
  • 建议10:妊娠期肝内胆汁淤积症诊断基于瘙痒情况下血清胆汁酸水平>10 μmol/L,通常发生于妊娠中期或晚期;应给予口服熊去氧胆酸总日剂量10-15 mg/kg治疗。

临床怎么用

  • 建议11:对子痫前期、HELLP综合征和妊娠急性脂肪肝等妊娠特有肝病的管理需要计划分娩并及时评估可能的肝移植;对有子痫前期或HELLP综合征风险的患者建议从妊娠第12周开始每日阿司匹林预防。
  • 建议12:慢性乙型肝炎病毒感染患者应检测血清HBV DNA和肝脏生化指标;未治疗但妊娠晚期血清HBV DNA>200,000 IU/mL者应考虑替诺福韦二吡呋酯治疗。
  • 建议13:因慢性肝病或肝移植后接受免疫抑制治疗的患者妊娠期应继续治疗并使用最低有效剂量;妊娠期不应使用吗替麦考酚酯。

局限性

  • 因未进行正式系统评价,这些最佳实践建议未附正式的证据质量或推荐强度分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available published evidence and expert advice regarding the clinical management of patients with pregnancy-related gastrointestinal and liver disease. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through the standard procedures of Gastroenterology. This article provides practical advice for the management of pregnant patients with gastrointestinal and liver disease based on the best available published evidence. The Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because formal systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: To optimize gastrointestinal and liver disease before pregnancy, preconception and contraceptive care counseling by a multidisciplinary team should be encouraged for reproductive-aged persons who desire to become pregnant. BEST PRACTICE ADVICE 2: Procedures, medications, and other interventions to optimize maternal health should not be withheld solely because a patient is pregnant and should be individualized after an assessment of the risks and benefits. BEST PRACTICE ADVICE 3: Coordination of birth for a pregnant patient with complex inflammatory bowel disease, advanced cirrhosis, or a liver transplant should be managed by a multidisciplinary team, preferably in a tertiary care center. BEST PRACTICE ADVICE 4: Early treatment of nausea and vomiting of pregnancy may reduce progression to hyperemesis gravidarum. In addition to standard diet and lifestyle measures, stepwise treatment consists of symptom control with vitamin B6 and doxylamine, hydration, and adequate nutrition; ondansetron, metoclopramide, promethazine, and intravenous glucocorticoids may be required in moderate to severe cases. BEST PRACTICE ADVICE 5: Constipation in pregnant persons may result from hormonal, medication-related, and physiological changes. Treatment options include dietary fiber, lactulose, and polyethylene glycol-based laxatives. BEST PRACTICE ADVICE 6: Elective endoscopic procedures should be deferred until the postpartum period, whereas nonemergent but necessary procedures should ideally be performed in the second trimester. Pregnant patients with cirrhosis should undergo evaluation for, and treatment of, esophageal varices; upper endoscopy is suggested in the second trimester (if not performed within 1 year before conception) to guide consideration of nonselective β-blocker therapy or endoscopic variceal ligation. BEST PRACTICE ADVICE 7: In patients with inflammatory bowel disease, clinical remission before conception, during pregnancy, and in the postpartum period is essential for improving outcomes of pregnancy. Biologic agents should be continued throughout pregnancy and the postpartum period; use of methotrexate, thalidomide, and ozanimod must be stopped at least 6 months before conception. BEST PRACTICE ADVICE 8: Endoscopic retrograde cholangiopancreatography during pregnancy may be performed for urgent indications, such as choledocholithiasis, cholangitis, and some cases of gallstone pancreatitis. Ideally, endoscopic retrograde cholangiopancreatography should be performed during the second trimester, but if deferring the procedure may be detrimental to the health of the patient and fetus, a multidisciplinary team should be convened to decide on the advisability of endoscopic retrograde cholangiopancreatography. BEST PRACTICE ADVICE 9: Cholecystectomy is safe during pregnancy; a laparoscopic approach is the standard of care regardless of trimester, but ideally in the second trimester. BEST PRACTICE ADVICE 10: The diagnosis of intrahepatic cholestasis of pregnancy is based on a serum bile acid level >10 μmol/L in the setting of pruritus, typically during the second or third trimester. Treatment should be offered with oral ursodeoxycholic acid in a total daily dose of 10-15 mg/kg. BEST PRACTICE ADVICE 11: Management of liver diseases unique to pregnancy, such as pre-eclampsia; hemolysis, elevated liver enzymes, and low platelets syndrome; and acute fatty liver of pregnancy requires planning for delivery and timely evaluation for possible liver transplantation. Daily aspirin prophylaxis for patients at risk for pre-eclampsia or hemolysis, elevated liver enzymes, and low platelets syndrome is advised beginning at week 12 of gestation. BEST PRACTICE ADVICE 12: In patients with chronic hepatitis B virus infection, serum hepatitis B virus DNA and liver biochemical test levels should be ordered. Patients not on treatment but with a serum hepatitis B virus DNA level >200,000 IU/mL during the third trimester of pregnancy should be considered for treatment with tenofovir disoproxil fumarate. BEST PRACTICE ADVICE 13: In patients on immunosuppressive therapy for chronic liver diseases or after liver transplantation, therapy should be continued at the lowest effective dose during pregnancy. Mycophenolate mofetil should not be administered during pregnancy.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kothari S, Afshar Y, Friedman LS, et al. AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review. Gastroenterology. 2024. PMID: 39140906. doi:10.1053/j.gastro.2024.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。